Ask about this productRelated genes to: IGFBP4 antibody
- Gene:
- IGFBP4 NIH gene
- Name:
- insulin like growth factor binding protein 4
- Previous symbol:
- -
- Synonyms:
- IBP4, BP-4, HT29-IGFBP, IGFBP-4
- Chromosome:
- 17q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-09
- Date modifiied:
- 2015-11-12
Related products to: IGFBP4 antibody
Related articles to: IGFBP4 antibody
- Hypertension is a major modifiable risk factor for chronic kidney disease (CKD), yet predicting which hypertensive individuals will progress to CKD remains challenging. We aimed to develop and validate a plasma protein-based risk score for incident CKD in hypertension and to identify causal proteins and potential therapeutic targets. - Source: PubMed
Publication date: 2026/04/22
Huang YuChen DanYe ZiliangZhang YanjunYang SisiGan XiaoqinZhang YiweiWu YitingZhang YuanyuanQin Xianhui - Laryngotracheal stenosis (LTS) is a fibroproliferative disease of the upper airway characterised by dysregulated extracellular matrix deposition and fibroblast activation. AlkB Homologue 5 (ALKBH5) has emerged as a key regulator of disease pathogenesis by modulating mRNA stability, yet its role in LTS remains unclear. - Source: PubMed
Wang JingLiao ZiweiXu MengrouZheng YangyangHu BinXia QianhuiXu Hongming - Hypodontia, defined as the congenital absence of teeth, may reflect underlying disturbances in molecular pathways regulating odontogenesis. This pilot cross-sectional study aimed to investigate whether systemic levels of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and human growth hormone (HGH) differ between individuals with congenital bilateral absence of mandibular second premolars and individuals with normal dentition. - Source: PubMed
Publication date: 2026/01/12
Alenzi Rana HAlshammari Abdullah FAbdullah Mashan LAldukhyeel Sultan MAldosari Mohammed NAljameel Yousef I - Pathological cardiac hypertrophy, a major contributor to heart failure, is characterized by an abnormal increase in the size of atria and ventricles. In the context of ventricular hypertrophy, the right ventricle (RV) exhibits less resistance to hypertrophy than the left one (LV). Insulin-like growth factors (IGF-1 and IGF-2) are critical for cell growth and provide cardioprotective effects. Pregnancy-associated plasma protein-A (PAPP-A) is a protease that cleaves insulin-like growth factor-binding protein-4 (IGFBP-4) and enhances IGF bioavailability. This study investigated PAPP-A-mediated IGFBP-4 proteolysis-one possible mechanism of IGF release regulation in rat models of right ventricular (RVH) and left ventricular (LVH) hypertrophy. RVH was induced with monocrotaline, and LVH via renovascular hypertension (1 Kidney 1 Clip (1K1C) model). Systolic blood pressure was measured using tail-cuff plethysmography. Heart morphometry was used to assess the mass of cardiac chambers. Cardiomyocyte purity was confirmed via troponin I immunocytochemistry. Plasma natriuretic type-B peptide (BNP) and C-terminal IGFBP-4 (CT-IGFBP-4) concentrations were quantified by fluoroimmunoassay. RVH and LVH were successfully modelled, with 1.6-fold and 1.3-fold increases in RV ( < 0.0001) and LV masses ( < 0.05), respectively. Plasma BNP was 2-3 times higher in LVH versus control rats. Hypertrophied cardiomyocytes secreted significantly more BNP than controls, showing 3.3-fold and 4.1-fold increases in LVH and RVH, respectively. PAPP-A-mediated IGFBP-4 proteolysis was 4-fold higher in RVH compared to control, but unaffected in LVH. These findings suggest that PAPP-A-specific elevation of IGFBP-4 proteolysis occurs predominantly in RVH, suggesting a differential IGF bioavailability in both ventricles and highlighting PAPP-A as a potential target to increase RVH resistance to hypertrophy. - Source: PubMed
Publication date: 2026/03/18
Artemieva Marina MMakeeva Arina VAdasheva Daria AShein Viacheslav EKatrukha Alexey GPostnikov Alexander BMedvedeva Natalia ASerebryanaya Daria V - Emphysema is an important chronic obstructive pulmonary disease (COPD) phenotype characterized by the destruction of air spaces distal to the terminal bronchiole. Aiming to detect potential emphysema biomarkers and to assess the systemic effects of emphysema in blood plasma, we conducted a small cross-sectional shotgun proteomics study. This study included N = 40 participants divided into four subgroups (N = 10 per group): patients with emphysema and COPD (CE), patients with COPD but without emphysema (CN), healthy smokers (HS) and healthy never-smokers (HN). The participants were sampled non-probabilistically to be similar in terms of age, sex and comorbidities. Participants' blood plasma was analyzed using liquid chromatography-mass spectrometry. Bioinformatic analysis included detection of differentially expressed proteins (DEPs) and overrepresentation analysis (ORA). Across all groups, a total of 994 proteins were identified, with NADP-dependent malic enzyme (NADP-ME; encoded by ) being the only DEP in the CE vs. CN contrast. Proteins such as BMP1, ADAMTSL-2, -4 and IGFBP4, -5, 6 were identified to be upregulated in CE vs. HN. Fibulin-1, -3 and several immunoglobulin components were identified to be downregulated in the CE vs. HN contrast. ORA revealed several enriched processes, including serine-type endopeptidase activity, insulin-like growth factor I and II binding, and signaling receptor binding. We propose NADP-ME, an important enzyme of intermediary metabolism and redox homeostasis, as a potential biomarker candidate of emphysema. Notably, NADP-ME is also implicated in anoikis resistance. Additionally, changes in the expression levels of BMP1, ADAMTSL-2 and -4, and fibulin suggest potential major systemic effects of extracellular matrix perturbation. As all data was derived from LC-MS analysis, these findings need to be further evaluated with complementary methods. - Source: PubMed
Publication date: 2026/03/21
Salai GrgurNovak RuđerHrkač StelaPustka VáclavPotěšil DavidZdráhal ZbyněkLjubicic DivoGrgurević Lovorka